111 Capital Grows Stake in Viking Therapeutics, Inc. $VKTX

111 Capital raised its stake in shares of Viking Therapeutics, Inc. (NASDAQ:VKTX) by 62.4% during the second quarter, HoldingsChannel reports. The firm owned 14,474 shares of the biotechnology company’s stock after buying an additional 5,559 shares during the quarter. 111 Capital’s holdings in Viking Therapeutics were worth $384,000 at the end of the most recent quarter.

Other institutional investors have also modified their holdings of the company. Nuveen LLC bought a new position in shares of Viking Therapeutics during the 1st quarter valued at approximately $9,283,000. Connor Clark & Lunn Investment Management Ltd. boosted its stake in Viking Therapeutics by 59.2% during the first quarter. Connor Clark & Lunn Investment Management Ltd. now owns 597,515 shares of the biotechnology company’s stock worth $14,430,000 after buying an additional 222,293 shares during the period. Woodline Partners LP increased its position in Viking Therapeutics by 222.7% during the first quarter. Woodline Partners LP now owns 301,078 shares of the biotechnology company’s stock valued at $7,271,000 after acquiring an additional 207,784 shares during the last quarter. Granahan Investment Management LLC increased its position in Viking Therapeutics by 20.4% during the first quarter. Granahan Investment Management LLC now owns 367,961 shares of the biotechnology company’s stock valued at $8,886,000 after acquiring an additional 62,375 shares during the last quarter. Finally, Cetera Investment Advisers raised its stake in shares of Viking Therapeutics by 67.5% in the first quarter. Cetera Investment Advisers now owns 144,349 shares of the biotechnology company’s stock valued at $3,486,000 after acquiring an additional 58,168 shares during the period. 76.03% of the stock is owned by institutional investors.

Viking Therapeutics Stock Performance

VKTX stock opened at $29.72 on Monday. Viking Therapeutics, Inc. has a one year low of $18.92 and a one year high of $81.73. The firm has a market cap of $3.34 billion, a price-to-earnings ratio of -19.42 and a beta of 0.64. The firm has a 50-day simple moving average of $29.30 and a two-hundred day simple moving average of $27.91.

Viking Therapeutics (NASDAQ:VKTX) last posted its quarterly earnings data on Wednesday, July 23rd. The biotechnology company reported ($0.58) EPS for the quarter, missing the consensus estimate of ($0.44) by ($0.14). The business’s revenue for the quarter was up NaN% on a year-over-year basis. During the same period in the previous year, the company posted ($0.20) EPS. As a group, equities analysts predict that Viking Therapeutics, Inc. will post -1.56 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts recently commented on VKTX shares. HC Wainwright reiterated a “buy” rating and set a $102.00 price target on shares of Viking Therapeutics in a report on Monday, September 29th. Weiss Ratings restated a “sell (d-)” rating on shares of Viking Therapeutics in a research report on Saturday, September 27th. Raymond James Financial cut their target price on Viking Therapeutics from $125.00 to $122.00 and set a “strong-buy” rating on the stock in a research note on Thursday, July 24th. Citigroup raised their price target on Viking Therapeutics from $31.00 to $38.00 and gave the stock a “neutral” rating in a research note on Thursday, July 24th. Finally, BTIG Research reaffirmed a “buy” rating and issued a $125.00 price objective on shares of Viking Therapeutics in a research report on Monday, September 22nd. Two research analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Viking Therapeutics has an average rating of “Moderate Buy” and a consensus target price of $86.42.

About Viking Therapeutics

Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD.